Skin Biopsy Segment by Screening Type to Lead Skin Cancer Diagnostics Market During 2021-2028

According to our latest study on "Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type and Screening Type " the market size is projected to reach US$ 5,480.45 million by 2028 from US$ 3,364.46 million in 2021; it is estimated to grow at a CAGR of 7.2% from 2021 to 2028. The report highlights the key factors and trends impacting the skin cancer diagnostics market and focuses on prominent players and their game-changing strategies.

The increasing incidence of skin cancer and launch of new products drive the market growth. However, the tedious and barriers to early skin cancer diagnostics in low and middle-income countries hampers the market growth.

Based on screening type, the global skin cancer diagnostics market is segmented into blood tests, dermatoscopy, imaging tests, lymph node biopsy, and skin biopsy. The skin biopsy segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period.

Skin biopsy segment held the largest market share for skin cancer diagnostics market. Skin biopsy is diagnosis procedure that require a small sample of the skin. During the skin biopsy procedure, doctor cuts and removes a small part from skin for the test. Skin biopsy is performed to determine skin cancer, infection or other skin conditions. The skin samples are collected by different types of biopsies such as punch, excisional, incisional, and shave biopsy. These types of biopsies are performed for melanoma skin cancer. And in cases of non-melanoma, biopsy is often the only test done to diagnose the stage or the extension of the cancer as non-melanoma skin cancer rarely spreads. Similar, to other mean of screening biopsy is equally important to diagnose a skin cancer type. The increasing awareness and incidences of skin cancer are likely to drive the market during the forecast period.

SkylineDx BV; AMLo Biosciences Limited; NeraCare GmbH; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; HOFFMANN-LA ROCHE LTD., and Michelson Diagnostics Ltd are among the leading companies operating in the global skin cancer diagnostics market.

By screening type, dermatoscpy segment is the second largest shareholder of skin cancer diagnostics market. Dermatoscopy is the primary test for skin cancer, it increases the sensitivity for detecting skin cancer, decreases the number of benign lesions biopsied for each malignant diagnosis, and enables the diagnosis of thinner melanomas compared with naked eye examination. Addition, dermatoscopy is cost effective, which is leading to decreased number of excised benign lesions. Furthermore, the advancements in the technology are enabling players to launch upgraded versions of their existing dermatoscopes and new dermatoscopes in the market. Thus, the above-listed factors are vitally contributing to the growth of market.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com